IOVA Quote, Financials, Valuation and Earnings

Lantheus Holdings, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of 7.23%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Lantheus Holdings, Inc.'s return on equity of 14.66%.

Iovance Biotherapeutics, Inc. has a consensus price target of $8.25, signalling upside risk potential of 273.3%. On the other hand Lantheus Holdings, Inc. has an analysts' consensus of $80.93 which suggests that it could grow by 35.4%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Lantheus Holdings, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.827, which suggesting that the stock is 17.288% less volatile than S&P 500. In comparison Lantheus Holdings, Inc. has a beta of -0.102, suggesting its less volatile than the S&P 500 by 110.17%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lantheus Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Lantheus Holdings, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are smaller than Lantheus Holdings, Inc. quarterly revenues of $384M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Lantheus Holdings, Inc.'s net income of $27.8M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Lantheus Holdings, Inc.'s PE ratio is 25.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 2.93x versus 2.73x for Lantheus Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Talphera, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of -443600%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Talphera, Inc.'s return on equity of -127.04%.

Iovance Biotherapeutics, Inc. has a consensus price target of $8.25, signalling upside risk potential of 273.3%. On the other hand Talphera, Inc. has an analysts' consensus of $3.25 which suggests that it could grow by 150%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Talphera, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Talphera, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.827, which suggesting that the stock is 17.288% less volatile than S&P 500. In comparison Talphera, Inc. has a beta of 0.248, suggesting its less volatile than the S&P 500 by 75.207%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Talphera, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Talphera, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Talphera, Inc. quarterly revenues of $1K. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Talphera, Inc.'s net income of -$4.4M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Talphera, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 2.93x versus 1,491.40x for Talphera, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Travere Therapeutics, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of 15.59%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.

Iovance Biotherapeutics, Inc. has a consensus price target of $8.25, signalling upside risk potential of 273.3%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.5000 which suggests that it could grow by 19.08%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Travere Therapeutics, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Travere Therapeutics, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.827, which suggesting that the stock is 17.288% less volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 2.93x versus 7.26x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenetic Biosciences, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of -49.65%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Xenetic Biosciences, Inc.'s return on equity of -59.39%.

Iovance Biotherapeutics, Inc. has a consensus price target of $8.25, signalling upside risk potential of 273.3%. On the other hand Xenetic Biosciences, Inc. has an analysts' consensus of -- which suggests that it could grow by 1552.89%. Given that Xenetic Biosciences, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than Iovance Biotherapeutics, Inc..

Iovance Biotherapeutics, Inc. has a beta of 0.827, which suggesting that the stock is 17.288% less volatile than S&P 500. In comparison Xenetic Biosciences, Inc. has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.837%.

Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenetic Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Xenetic Biosciences, Inc. pays out -- of its earnings as a dividend.

Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Xenetic Biosciences, Inc. quarterly revenues of $1M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Xenetic Biosciences, Inc.'s net income of -$509.9K. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Xenetic Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 2.93x versus 1.31x for Xenetic Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.